We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mouse Model Suggests Mechanism for Development of Atherosclerosis

By Biotechdaily staff writers
Posted on 07 May 2003
Researchers working with a mouse model have found that inactivation of the low-density lipoprotein receptor-related protein (LRP1) in vascular smooth muscle cells (SMCs) causes overexpression of the receptor for platelet-derived growth factor (PDGF) and abnormal activation of PDGF signaling, resulting in disruption of the elastic layer, SMC proliferation, aneurysm formation, and marked susceptibility to cholesterol-induced atherosclerosis. More...


"We used gene targeting to unravel a mechanism that controls and holds smooth muscle cell proliferation and migration in check,” said first author Dr. Philippe Boucher, postdoctoral researcher in molecular genetics at the University of Texas Southwestern Medical Center (Dallas, USA; www.utsouthwestern.edu). "This process is hyperactive in atherosclerosis.”

The findings were reported in the April 11, 2003, issue of Science. The investigators also reported that Gleevec, an inhibitor of PDGF signaling used successfully to treat chronic myeloid leukemia, was able to reduce atherosclerosis in the mouse model by about 50%.

There is no human clinical condition similar to that of the mouse model lacking LRP1. Nonetheless, this study emphasized the importance of PDGF signaling in the development of atherosclerosis.




Related Links:
University of Texas Southwestern Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.